{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:24:12Z","timestamp":1785803052314,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.cct.2022.106755","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T11:52:00Z","timestamp":1649073120000},"page":"106755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design"],"prefix":"10.1016","volume":"116","author":[{"given":"Konrad","family":"Rejdak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Fiedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bonek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Goch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Gala-B\u0142\u0105dzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Che\u0142stowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"\u0141ukasiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"Kiciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"D\u0105browski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Dec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew J.","family":"Kr\u00f3l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Papu\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Zasybska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Segiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Grieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2022.106755_bb0005","doi-asserted-by":"crossref","first-page":"e1003346","DOI":"10.1371\/journal.pmed.1003346","article-title":"Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis","volume":"17","author":"Buitrago-Garcia","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.cct.2022.106755_bb0010","first-page":"1","article-title":"Incubation period for COVID-19: a systematic review and meta-analysis","author":"Rai","year":"2021","journal-title":"Z Gesundh Wiss"},{"key":"10.1016\/j.cct.2022.106755_bb0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.cct.2022.106755_bb0020","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.2020.22813","article-title":"Therapy for early COVID-19: a critical need","volume":"324","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2022.106755_bb0025","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1002\/jmv.26873","article-title":"Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity","volume":"93","author":"Bramante","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cct.2022.106755_bb0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jamda.2020.10.031","article-title":"Metformin is associated with decreased 30-day mortality among nursing home residents infected with SARS-CoV2","volume":"22","author":"Lally","year":"2021","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.cct.2022.106755_bb0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00406-020-01231-x","article-title":"Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor","volume":"271","author":"Hashimoto","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.cct.2022.106755_bb0040","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2022.106755_bb0045","doi-asserted-by":"crossref","first-page":"ofab050","DOI":"10.1093\/ofid\/ofab050","article-title":"Prospective cohort of fluvoxamine for early treatment of Coronavirus Disease 19","volume":"8","author":"Seftel","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cct.2022.106755_bb0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.14802\/jmd.20042","article-title":"COVID-19: an early review of its global impact and considerations for Parkinson\u2019s disease patient care","volume":"13","author":"Bhidayasiri","year":"2020","journal-title":"J Mov Disord"},{"key":"10.1016\/j.cct.2022.106755_bb0055","doi-asserted-by":"crossref","first-page":"102163","DOI":"10.1016\/j.msard.2020.102163","article-title":"Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment","volume":"42","author":"Rejdak","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.cct.2022.106755_bb0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5114\/fn.2021.107572","article-title":"Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?","volume":"59","author":"Grieb","year":"2021","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.cct.2022.106755_bb0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00702-021-02306-2","article-title":"Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials","volume":"128","author":"Danysz","year":"2021","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.cct.2022.106755_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug resistance in influenza a virus: the epidemiology and management","volume":"10","author":"Hussain","year":"2017","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cct.2022.106755_bb0075","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40263-018-0552-2","article-title":"Amantadine extended-release (GOCOVRITM): a review in levodopa-induced dyskinesia in Parkinson\u2019s disease","volume":"32","author":"Paik","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.cct.2022.106755_bb0080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2217\/nmt-2020-0030","article-title":"Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis","volume":"10","author":"Perez","year":"2020","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.cct.2022.106755_bb0085","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40360-020-0391-x","article-title":"Antiviral treatment perspective against Borna disease virus 1 infection in major depression: a double-blind placebo-controlled randomized clinical trial","volume":"21","author":"Dietrich","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.cct.2022.106755_bb0090","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/jpm10040217","article-title":"Anti-inflammatory effects of amantadine and Memantine: possible therapeutics for the treatment of Covid-19?","volume":"10","author":"Jim\u00e9nez-Jim\u00e9nez","year":"2020","journal-title":"J Pers Med"},{"key":"10.1016\/j.cct.2022.106755_bb0095","first-page":"1","article-title":"Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2","author":"Cort\u00e9s-Borra","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.cct.2022.106755_bb0100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jmv.26179","article-title":"Use of amantadine in a patient with SARS-CoV-2","volume":"93","author":"Aranda-Abreu","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cct.2022.106755_bb0105","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41594-020-00536-8","article-title":"Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers","volume":"27","author":"Mandala","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.cct.2022.106755_bb0110","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/acsptsci.0c00172","article-title":"Docking prediction of amantadine in the receptor binding domain of spike protein of SARS-CoV-2","volume":"3","author":"Baig","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.cct.2022.106755_bb0115","doi-asserted-by":"crossref","first-page":"589505","DOI":"10.3389\/fcimb.2020.589505","article-title":"Cathepsin L in COVID-19: from pharmacological evidences to genetics","volume":"10","author":"Gomes","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.cct.2022.106755_bb0120","doi-asserted-by":"crossref","first-page":"106004","DOI":"10.1016\/j.ijantimicag.2020.106004","article-title":"Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment","volume":"55","author":"Smieszek","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.cct.2022.106755_bb0125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","article-title":"Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.cct.2022.106755_bb0130","author":"WHO"},{"key":"10.1016\/j.cct.2022.106755_bb0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cct.2022.106755_bb0140","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/jcph.1802","article-title":"Amantadine for COVID-19","volume":"61","author":"Grieb","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cct.2022.106755_bb0145","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s42255-020-0237-2","article-title":"A metabolic handbook for the COVID-19 pandemic","volume":"2","author":"Ayres","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.cct.2022.106755_bb0150","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/1570159X19666210729123734","article-title":"Fluvoxamine and amantadine: central nervous system acting drugs repositioned for COVID-19 as early intervention","volume":"20","author":"Rejdak","year":"2022","journal-title":"Curr. Neuropharmacol."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714422000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:55:35Z","timestamp":1761555335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714422000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":30,"alternative-id":["S1551714422000817"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2022.106755","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2022.106755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106755"}}